- Sofia Ioannidou joined Andera Partners’ BioDiscovery team in 2009 as an Associate. She was promoted to Partner in 2019.
- Prior to Andera Partners, Sofia was part of the Life Sciences team of L.E.K. Consulting London, from 2006 to 2008, having started her career in R&D with Boston-based Eyetech Pharmaceuticals, Inc., from 2003 to 2006.
- Since 2009, she has actively contributed to a number of investments, trade sales and IPOs. Sofia currently serves on the board of Tricares, Avalyn, Exciva and PegaOne and has previously served on the boards of LogicBio and Sanifit.
- She holds a PhD in Cell Biology from Cancer Research UK and an MBiochem from the University of Oxford.
- Sofia is a native Greek speaker and also speaks English, French and Spanish.
4 languages spoken
Investments of Sofia
Avalyn Pharma
Inhaled anti-fibrotic drug for the treatment of orphan respiratory disease
LogicBio
Gene therapy for the treatment of rare diseases in infants
Tricares
Prothèse de valve tricuspide
Sanifit
Phytic acid for the treatment of cardiovascular calcification
Oncoethix
Small molecules for haematological cancer treatment
CHASE Pharmaceuticals
Novel approach to increase efficacy and safety of marketed Alzheimer's drugs
Tobira Therapeutics
Mocules for the treatment of inflammatory diseases
Exciva
Small molecule for the treatment of behavioral and psychological symptoms of dementia in AD
The team BioDiscovery
Thierry Hercend
Venture Partner
Aneta Sottil
Director
Mathieu Piéronne
Investment manager
Raphaël Wisniewski
Partner
Sofia Ioannidou
Partner
Gilles Nobécourt
Partner
Olivier Litzka
Partner
Loan Hoang-Sayag
Venture Partner
Denis Dubuy
Investment manager
Claire Catherinet
Analyst
Elyes Chouaieb
Analyst
Emmanuelle Payet
Middle Office
Michael Hayden
Venture Advisor
Raymond W. Cohen
Venture Advisor
Vanessa Bonvalot
Executive Assistant